Did You Know...
...In 1790, the cost to obtain a patent was between $4 and $5.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7981434 | Surface exposed immunoglobulin D-binding protein from The present invention relates to a surface exposed protein, which can be detected in Moraxella catarrhalis, having an amino acid sequence as described in SEQ ID NO: 1, an apparent molecular weight of 200 kDa and a capacity of selectively binding membrane boun... | 07/19/2011 |
| 7427404 | Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the aminoacid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly 44, Thr... | 09/23/2008 |
| 7393535 | Adjuvants for use in vaccines The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal. ... | 07/01/2008 |
| 7285289 | Nanoparticle vaccines The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also displa... | 10/23/2007 |
| 7279169 | Mucosal DTPa vaccines Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a muco... | 10/09/2007 |
| 7211263 | Use of adenylate cyclase or bacteria producing it as vaccines against The invention relates to a method of immunizing a mammal against infection by a first Bordetella species. The method comprises administering to the mammal a preparation comprising a portion of the amino acid sequence of mature adenylate cyclase of a second | 05/01/2007 |
| RE39494 | Inactivated mycoplasma hyopneumoniae and uses therefor The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The r... | 02/27/2007 |
| 7105317 | Immunogenic compositions comprising vrg-gene products from extracts This invention relates to an immunogenic composition comprising a bacterial extract containing at least one expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis, B. parapertussis, or B. bronchiseptica. The inve... | 09/12/2006 |
| 7105161 | Proteinaceous adjuvants A modulated immune response to an antigen is achieved by coadministering the antigen and a genetically-detoxified pertussis holotoxin, particularly one retaining its immunogenicity, to a host. The modulated immune response enables immunogenic compositions, in... | 09/12/2006 |
| 7087236 | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof A method of inducing either a TH1 polarized immune response, a TH2 polarized immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for indu... | 08/08/2006 |
| 7070781 | Nontoxic mucosal adjuvant A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating t... | 07/04/2006 |
| 7070779 | POLYPEPTIDES CONTAINING POLYMORPHISMS OF THE REPEATED REGIONS OF PERTACTIN IN BORDETELLA PERTUSSIS, BORDETELLA PARAPERTUSSIS, AND BORDETELLA BRONCHISEPTICA, THEIR USE IN DIAGNOSTICS, AND IN IMMUNOGENIC COMPOSITIONS Pertactin (PRN) is an outer membrane protein expressed by Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica, which induces protective immunity to Bordetella infections. The immunodominant and immunoprotective epitopes... | 07/04/2006 |
| 7056521 | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli (LT). ... | 06/06/2006 |
| 6929794 | IL-12 as an adjuvant for Bordetella pertussis vaccines This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with ... | 08/16/2005 |
| 6890530 | Composition comprising fungi of genus trichoderma used as biological control agent and the applications thereof The composition includes fingi belonging to one or more species of fungi of the genus Trichoderma, selected from T. asperellum, T. atroviride, T. inhamatum and their mixtures, useful as an agent for the biological control of phytopathogenic organisms. ... | 05/10/2005 |
| 6887484 | Vaccine composition containing a promoter peptide A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a p... | 05/03/2005 |
| 6814971 | Adjuvants for use in vaccines The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal. ... | 11/09/2004 |
| 6733754 | Adjuvants for use in vaccines The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal. ... | 05/11/2004 |
| 6713072 | Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating, a microorganism transformed with a hybrid plasmid including the gene... | 03/30/2004 |
| 6696065 | Acellular pertussis vaccines and methods of preparation thereof A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide on Haemophilus in... | 02/24/2004 |
| 6660261 | Bordetella strain expressing the FHA hybrid, liposomes and vaccines The invention concerns a Bordetella strain deficient in the production of toxin and expressing a hybrid protein comprising at least part of the filamentous hemagglutin (FHA) and at least part of a protein heterologous to FHA. The gene coding for the toxin... | 12/09/2003 |
| 6572861 | Adjuvants for use in vaccines The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.... | 06/03/2003 |
| 6562352 | Vaccine compositions for mucosal delivery The invention provides the use of an antigen which is a mucosally immunogenically active substance comprising the 50 kD C fragment of tetanus toxin, an immunogenic fragment thereof, or a derivative thereof formed by amino acid deletion, substitution or in... | 05/13/2003 |
| 6517844 | Compositions and method for immunizing polutry The present invention is directed to vaccine compositions and methods for immunizing poultry. The vaccine compositions comprise inactivated bacterial organisms which can be administered to the poultry through oral intake of water.... | 02/11/2003 |
| 6485946 | Production of chitosan and chitin The invention relates to a method of producing chitin or chitosan by culturing a Rhizopus azygosporus fungus or an Actinomucor taiwanensis fungus and isolating chitosan or chitin from the culture.... | 11/26/2002 |
| 6399076 | Acellular pertussis vaccines and methods of preparation thereof Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be... | 06/04/2002 |
| 6387377 | Acellular antibordetella vaccine The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. Tertussis, B. parapertussis or B. bron... | 05/14/2002 |
| 6368589 | Use of autologous promoters to express gene products in Bordetella Autologous promoters are used to effect expression of gene products in Bordetella strains. Hybrid Bordetella genes are constructed comprising a Bordetella gene, particularly one encoding a Bordetella antigen, fused at an ATG codon to a native but autologo... | 04/09/2002 |
| 6309648 | Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections The subject of the invention is amino acid sequences of the AC-Hly from B. pertussis. B. parapertussis and/or B. bronchiseptica, carrying epitopes capable of inducing a protective immune response against infection by Bordetella. The subject of the inventi... | 10/30/2001 |
| 6284256 | Bordetella bronchiseptica vaccine The present invention is concerned with a vaccine for combating B. bronchiseptica infection in susceptible animals (such as dogs and swine), containing proteins or polypeptides typical of the fimbrial protein of B. bronchiseptica, or containing recombinan... | 09/04/2001 |
| 6251606 | Gene sequence and method for distinguishing cordyceps sinensis The present invention utilizes the singularity of the 18S rRNA gene sequence of the Cordyceps sinensis between the NS3/NS6 primer pair as the index for distinguishing the Cordyceps sinensis from other Cordyceps species.... | 06/26/2001 |
| 6214356 | Use of adenylate cyclase or bacteria producing it as vaccines against bordetella The invention relates to a method for immunizing a mammal against infection by a first Bordetella species. The method comprises administering to the mammal a preparation comprising a portion of the amino acid sequence of mature adenylate cyclase of a seco... | 04/10/2001 |
| 6210685 | Antigenic preparations and isolation of such preparations The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B. pertussis, the said preparations being useful as components of acellular whooping cough vaccines. Th... | 04/03/2001 |
| 6162433 | Non antibiotic selectable markers for live vaccines The invention relates to DNA constructs encoding a safe, selectable marker, other than an antibiotic resistance marker, vectors and/or cells including said constructs; and vaccines based on said constructs for use in animals and particularly humans. The s... | 12/19/2000 |
| 6127151 | Antigenic preparations and the isolation of such preparations A method of deriving an antigen from Bordetella pertussis, wherein the antigen is characterized by the following features: a relative molecular weight of about 67,000 to 73,000 as determined by 12%(w/w) polyacrylamide gel electrophoresis and a proline:glu... | 10/03/2000 |
| 6060067 | Process for the preparation of tetanus toxoid vaccine A process for the preparation of tetanus toxoid, which process comprises incubating purified tetanus toxin with 0.2 to 1% (v/v) formaldehyde in the presence of 0.005 to 0.25M lysine for from 24 to 32 days at a pH of from 6.0 to 8.0 and a temperature of fr... | 05/09/2000 |
| 6046224 | 12 (S)--hete receptor blockers The 12-lipoxygenase product, 12(S)-HETE, mediates hyperproliferative and hyperplastic responses seen in atherosclerosis, diabetes, Parkinson's disease, Alzheimer's, stroke-induced nerve damage and cancer. 12-HETE also mediates inflammation and cell death ... | 04/04/2000 |
| 6030625 | Bordetella pertussis and Bordetella parapertussis strains An immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (Ac-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of Bordetella chosen from B. pertussis, B. parapertussis or B. bronchiseptica, and in that i... | 02/29/2000 |
| 6019979 | Anti-viral treatment with pertussis toxin B oligomer There is disclosed a method for anti-viral therapy treatment with the Pertussis toxin beta subunit oligomer, wherein the oligomer is composed of from two to ten subunits of PTX selected from the group consisting of S2, S3, S4, S5, and combinations thereof... | 02/01/2000 |
| 6018022 | Modification of pertussis toxin The three-dimensional structure of crystalline pertussis holotoxin (PT) has been determined by X-ray crystallography. Crystal structures have also been determined for complexes of pertussis toxin with molecules relevant to the biological activity of PT. T... | 01/25/2000 |
